Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection

American Journal of Respiratory and Critical Care Medicine

Volumn 184, Issue 3, 2011, Pages 345-354

  Wargo, Matthew J ^a   Gross, Maegan J ^b   Rajamani, Sathish ^b   Allard, Jenna L ^a   Lundblad, Lennart K A ^a   Allen, Gilman B ^a   Vasil, Michael L ^c   Leclair, Laurie W ^a   Hogan, Deborah A ^b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Phospholipase; Pseudomonas; Respiratory mechanics; Surfactant

Indexed keywords

CHOLINE; LUNG SURFACTANT; MILTEFOSINE; PHOSPHOLIPASE C; SPHINGOMYELIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL STRAIN; CHRONIC DISEASE; CONTROLLED STUDY; CYSTIC FIBROSIS; EMERGENCY TREATMENT; IN VIVO STUDY; LUNG FUNCTION; LUNG INFECTION; LUNG LAVAGE; MALE; MORTALITY; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS; PSEUDOMONAS INFECTION; STATISTICAL SIGNIFICANCE; VIRULENCE;

ANIMALS; ANTIFUNGAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CYSTIC FIBROSIS; DISEASE MODELS, ANIMAL; HUMANS; INJECTIONS, INTRAPERITONEAL; LUNG; MICE; MICE, INBRED C57BL; OPPORTUNISTIC INFECTIONS; PHOSPHORYLCHOLINE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATION, ARTIFICIAL; RESPIRATORY TRACT INFECTIONS;

EID: 80051567668     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201103-0374OC     Document Type: Article

References (71)

1. Van Delden C, Iglewski BH. Cell-to-cell signaling and Pseudomonas aeruginosa infections. Emerg Infect Dis 1998;4:551-560. (Pubitemid 28553680)
2. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163. (Pubitemid 28334435)
3. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-574. (Pubitemid 26303478)
4. Rajan S, Saiman L. Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2002;17:47-56. (Pubitemid 34233391)
5. Craven DE. Preventing ventilator-associated pneumonia in adults: sowing seeds of change. Chest 2006;130:251-260. (Pubitemid 44116868)
6. Foglia E, Meier MD, Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. Clin Microbiol Rev 2007;20:409-425. (Pubitemid 47175011)
7. Rello J, Rodriguez R, Jubert P, Alvarez B. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Study Group for Severe Community-Acquired Pneumonia. Clin Infect Dis 1996;23:723-728. (Pubitemid 26331114)
8. Restrepo MI, Anzueto A. The role of gram-negative bacteria in healthcareassociated pneumonia. Semin Respir Crit Care Med 2009;30:61-66.
9. Sadikot RT, Blackwell TS, Christman JW, Prince AS. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med 2005;171:1209-1223. (Pubitemid 40740727)
10. Lanotte P, Mereghetti L, Lejeune B, Massicot P, Quentin R. Pseudomonas aeruginosa and cystic fibrosis: correlation between exoenzyme production and patient's clinical state. Pediatr Pulmonol 2003;36:405-412. (Pubitemid 37296701)
11. Nguyen D, Emond MJ, Mayer-Hamblett N, Saiman L, Marshall BC, Burns JL. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 2007;42:533-541. (Pubitemid 46870385)
12. Lopez DJ, Collado MI, Ibarguren M, Vasil AI, Vasil ML, Goni FM, Alonso A. Multiple phospholipid substrates of phospholipase c/sphingomyelinase HR2 from Pseudomonas aeruginosa. Chem Phys Lipids 2011;164:78-82.
13. Wiener-Kronish JP, Sakuma T, Kudoh I, Pittet JF, Frank D, Dobbs L, Vasil ML, Matthay MA. Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits. J Appl Physiol 1993;75:1661-1669. (Pubitemid 23318215)
14. Caminiti SP, Young SL. The pulmonary surfactant system. Hosp Pract (Off Ed) 1991;26:87-90, 94-100.
15. Lema G, Dryja D, Vargas I, Enhorning G. Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant. Pediatr Res 2000;47:121-126. (Pubitemid 30038901)
16. Wargo MJ, Ho TC, Gross MJ, Whittaker LA, Hogan DA. GbdR regulates Pseudomonas aeruginosa plcH and pchP transcription in response to choline catabolites. Infect Immun 2009;77:1103-1111.
17. Hull J, South M, Phelan P, Grimwood K. Surfactant composition in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997;156:161-165. (Pubitemid 27293182)
18. Meyer KC, Sharma A, Brown R, Weatherly M, Moya FR, Lewandoski J, Zimmerman JJ. Function and composition of pulmonary surfactant and surfactant-derived fatty acid profiles are altered in young adults with cystic fibrosis. Chest 2000;118:164-174. (Pubitemid 30485504)
19. Mander A, Langton-Hewer S, Bernhard W, Warner JO, Postle AD. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am J Respir Cell Mol Biol 2002;27:714-721. (Pubitemid 35381180)
20. Brogden KA. Changes in pulmonary surfactant during bacterial pneumonia. Antonie van Leeuwenhoek 1991;59:215-223.
21. Baughman RP, Stein E, MacGee J, Rashkin M, Sahebjami H. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin Chem 1984;30:521-523.
22. Griese M, Birrer P, Demirsoy A. Pulmonary surfactant in cystic fibrosis. Eur Respir J 1997;10:1983-1988. (Pubitemid 27406428)
23. Baughman RP, Sternberg RI, Hull W, Buchsbaum JA, Whitsett J. Decreased surfactant protein A in patients with bacterial pneumonia. Am Rev Respir Dis 1993;147:653-657. (Pubitemid 23072657)
24. LeVine AM, Lotze A, Stanley S, Stroud C, O'Donnell R, Whitsett J, Pollack MM. Surfactant content in children with inflammatory lung disease. Crit Care Med 1996;24:1062-1067. (Pubitemid 26189951)
25. Wu Y, Xu Z, Henderson FC, Ryan AJ, Yahr TL, Mallampalli RK. Chronic Pseudomonas aeruginosa infection reduces surfactant levels by inhibiting its biosynthesis. Cell Microbiol 2007;9:1062-1072. (Pubitemid 46394915)
26. Hayashida S, Harrod KS, Whitsett JA. Regulation and function of CCSP during pulmonary Pseudomonas aeruginosa infection in vivo. Am J Physiol Lung Cell Mol Physiol 2000;279:L452-L459.
27. Zhou J, Wu Y, Henderson F, McCoy DM, Salome RG, McGowan SE, Mallampalli RK. Adenoviral gene transfer of a mutant surfactant enzyme ameliorates Pseudomonas-induced lung injury. Gene Ther 2006;13:974-985. (Pubitemid 43827339)
28. Attalah HL, Wu Y, Alaoui-El-Azher M, Thouron F, Koumanov K, Wolf C, Brochard L, Harf A, Delclaux C, Touqui L. Induction of type-IIa secretory phospholipase A2 in animal models of acute lung injury. Eur Respir J 2003;21:1040-1045. (Pubitemid 36675623)
29. Holm BA, Keicher L, Liu MY, Sokolowski J, Enhorning G. Inhibition of pulmonary surfactant function by phospholipases. J Appl Physiol 1991;71:317-321.
30. Wargo MJ, Allard JL, Lundblad LKA, Hogan DA, Whittaker LA. The role of Pseudomonas aeruginosa plcH in alteration of lung physiology in a mouse model of infection. Pediatr Pulmonol 2008;43:292-293.
31. Wargo MJ, Rajamani S, Allard JL, Hogan DA, Whittaker LA. A small molecule inhibitor of PlcH protects against surfactant dysfunction and resultant lung injury in mice. Pediatr Pulmonol 2009;44:299.
32. Schweizer HD. Small broad-host-range gentamycin resistance gene cassettes for site-specific insertion and deletion mutagenesis. Biotechniques 1993;15:831-834.
33. Wargo MJ, Szwergold BS, Hogan DA. Identification of two gene clusters and a transcriptional regulator required for Pseudomonas aeruginosa glycine betaine catabolism. J Bacteriol 2008;190:2690-2699. (Pubitemid 351508169)
34. Mamessier E, Boniface S, Dupuy P, Reynaud-Gaubert M, Vervloet D, Magnan A. Study of cytokine gene expression in small cell samples: use in induced sputum. J Immunol Methods 2003;280:37-47. (Pubitemid 37289214)
35. Vasil ML, Stonehouse MJ, Vasil AI, Wadsworth SJ, Goldfine H, Bolcome RE III, Chan J. A complex extracellular sphingomyelinase of Pseudomonas aeruginosa inhibits angiogenesis by selective cytotoxicity to endothelial cells. PLoS Pathog 2009;5:e1000420.
36. Stonehouse MJ, Cota-Gomez A, Parker SK, Martin WE, Hankin JA, Murphy RC, Chen W, Lim KB, Hackett M, Vasil AI, et al. A novel class of microbial phosphocholine-specific phospholipases C. Mol Microbiol 2002;46:661-676. (Pubitemid 35365602)
37. Amiel E, Lovewell RR, O'Toole GA, Hogan DA, Berwin B. Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression. Infect Immun 2010;78:2937-2945.
38. Allen GB, Leclair T, Cloutier M, Thompson-Figueroa J, Bates JH. The response to recruitment worsens with progression of lung injury and fibrin accumulation in a mouse model of acid aspiration. Am J Physiol Lung Cell Mol Physiol 2007;292:L1580-L1589. (Pubitemid 47077374)
39. Lundblad LK, Thompson-Figueroa J, Allen GB, Rinaldi L, Norton RJ, Irvin CG, Bates JH. Airway hyperresponsiveness in allergically inflamed mice: the role of airway closure. Am J Respir Crit Care Med 2007;175:768-774. (Pubitemid 46631787)
40. Lundblad LK, Thompson-Figueroa J, Leclair T, Sullivan MJ, Poynter ME, Irvin CG, Bates JH. Tumor necrosis factor-alpha overexpression in lung disease: a single cause behind a complex phenotype. Am J Respir Crit Care Med 2005;171:1363-1370. (Pubitemid 40800508)
41. Wieland CW, Siegmund B, Senaldi G, Vasil ML, Dinarello CA, Fantuzzi G. Pulmonary inflammation induced by Pseudomonas aeruginosa lipopolysaccharide, phospholipase C, and exotoxin A: role of interferon regulatory factor 1. Infect Immun 2002;70:1352-1358. (Pubitemid 34163411)
42. Zhou X, Arthur G. Improved procedures for the determination of lipid phosphorus by malachite green. J Lipid Res 1992;33:1233-1236.
43. Hollsing AE, Granstrom M, Vasil ML, Wretlind B, Strandvik B. Prospective study of serum antibodies to Pseudomonas aeruginosa exoproteins in cystic fibrosis. J Clin Microbiol 1987;25:1868-1874. (Pubitemid 17149258)
44. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168:918-951. (Pubitemid 37267172)
45. Wagers S, Lundblad L, Moriya HT, Bates JH, Irvin CG. Nonlinearity of respiratory mechanics during bronchoconstriction in mice with airway inflammation. J Appl Physiol 2002;92:1802-1807. (Pubitemid 34666404)
46. Berka RM, Vasil ML. Phospholipase C (heat-labile hemolysin) of Pseudomonas aeruginosa: purification and preliminary characterization. J Bacteriol 1982;152:239-245. (Pubitemid 13199069)
47. Kennedy JI Jr. High alveolar surface tension pulmonary edema: relationship to adult respiratory distress syndrome. J Thorac Cardiovasc Surg 1990;100:145-146.
48. Allen GB, Pavone LA, DiRocco JD, Bates JH, Nieman GF. Pulmonary impedance and alveolar instability during injurious ventilation in rats. J Appl Physiol 2005;99:723-730. (Pubitemid 41061171)
49. Lundblad LK, Thompson-Figueroa J, Leclair T, Irvin CG, Bates JH. Thoracic gas volume measurements in paralyzed mice. Ann Biomed Eng 2004;32:1420-1427.
50. Ostroff RM, Wretlind B, Vasil ML. Mutations in the hemolyticphospholipase C operon result in decreased virulence of Pseudomonas aeruginosa PAO1 grown under phosphate-limiting conditions. Infect Immun 1989;57:1369-1373. (Pubitemid 19114149)
51. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science 1995;268:1899-1902.
52. Berman J. Current treatment approaches to leishmaniasis. Curr Opin Infect Dis 2003;16:397-401. (Pubitemid 37267258)
53. Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem 2007;14:1153-1169. (Pubitemid 46679457)
54. Pomerantsev AP, Kalnin KV, Osorio M, Leppla SH. Phosphatidylcholine- specific phospholipase C and sphingomyelinase activities in bacteria of the Bacillus cereus group. Infect Immun 2003;71:6591-6606. (Pubitemid 37337719)
55. Montes LR, Lopez DJ, Sot J, Bagatolli LA, Stonehouse MJ, Vasil ML, Wu BX, Hannun YA, Goni FM, Alonso A. Ceramide-enriched membrane domains in red blood cells and the mechanism of sphingomyelinaseinduced hot-cold hemolysis. Biochemistry 2008;47:11222-11230.
56. Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 2010;8:919-944.
57. Rakotomanga M, Blanc S, Gaudin K, Chaminade P, Loiseau PM. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob Agents Chemother 2007;51:1425-1430. (Pubitemid 46586825)
58. Huelves L, Del Prado G, Gracia M, Rodriguez-Cerrato V, Ponte C. In vitro and in vivo activity of miltefosine against penicillin-sensitive and -resistant Streptococcus pneumoniae strains. J Chemother 2008;20:441-444.
59. Llull D, Rivas L, Garcia E. In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci. Antimicrob Agents Chemother 2007;51:1844-1848. (Pubitemid 46744170)
60. Pankhaniya RR, Tamura M, Allmond LR, Moriyama K, Ajayi T, Wiener- Kronish JP, Sawa T. Pseudomonas aeruginosa causes acute lung injury via the catalytic activity of the patatin-like phospholipase domain of ExoU. Crit Care Med 2004;32:2293-2299. (Pubitemid 39491811)
61. Schmalzer KM, Benson MA, Frank DW. Activation of ExoU phospholipase activity requires specific C-terminal regions. J Bacteriol 2010;192:1801-1812.
62. Terada LS, Johansen KA, Nowbar S, Vasil AI, Vasil ML. Pseudomonas aeruginosa hemolytic phospholipase C suppresses neutrophil respiratory burst activity. Infect Immun 1999;67:2371-2376. (Pubitemid 29200495)
63. Meyers DJ, Berk RS. Characterization of phospholipase C from Pseudomonas aeruginosa as a potent inflammatory agent. Infect Immun 1990;58:659-666. (Pubitemid 20072628)
64. Graham LM, Vasil A, Vasil ML, Voelkel NF, Stenmark KR. Decreased pulmonary vasoreactivity in an animal model of chronic Pseudomonas pneumonia. Am Rev Respir Dis 1990;142:221-229. (Pubitemid 20224606)
65. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, et al. Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 2008;14:382-391. (Pubitemid 351499396)
66. Yu H, Zeidan YH, Wu BX, Jenkins RW, Flotte TR, Hannun YA, Virella-Lowell I. Defective acid sphingomyelinase pathway with Pseudomonas aeruginosa infection in cystic fibrosis. Am J Respir Cell Mol Biol 2009;41:367-375.
67. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the acute respiratory distress syndrome. J Intensive Care Med 2006;21:119-143.
68. Jimenez-Lopez JM, Carrasco MP, Segovia JL, Marco C. Hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis and the proliferation of Hepg2 cells. Eur J Biochem 2002;269:4649-4655.
69. Geilen CC, Wieder T, Reutter W. Hexadecylphosphocholine inhibits translocation of ctp:Choline-phosphate cytidylyltransferase in madindarby canine kidney cells. J Biol Chem 1992;267:6719-6724.
70. Wieder T, Orfanos CE, Geilen CC. Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 1998;273:11025-11031. (Pubitemid 28204945)
71. Marco C, Jimenez-Lopez JM, Rios-Marco P, Segovia JL, Carrasco MP. Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in Hepg2 cells. Int J Biochem Cell Biol 2009;41:1296-1303.